

Phytoestrogens: food or drug?

Lucia Bacciottini
 Alberto Falchetti
 Barbara Pampaloni
 Elisa Bartolini
 Anna Maria Carossino
 Maria Luisa Brandi

Department of Internal Medicine, University of Florence,
 Florence, Italy

Address for correspondence:
 Maria Luisa Brandi, M.D., Ph.D.
 Department of Internal Medicine
 University of Florence
 Viale Pieraccini 6, 50139 Florence, Italy
 Ph. +39-055-4296586
 Fax +39-055-4296585
 E-mail: m.brandi@dmi.unifi.it

Summary

Within the past several years, the relation between diet and health has been accepted by the mainstream nutrition community and in this connection interest in the physiological role of bioactive compounds present in plants has dramatically increased over the last decade.

The phytoestrogens are bioactive molecules present as nutritional constituents of widely consumed vegetables. Their name derives from the fact that they are able to bind to estrogen receptors and to induce an estrogenic/antiestrogenic response in target tissues. Natural estrogens are involved in a multiplicity of programmed events in target tissues as uterus, breast, pituitary gland and hormone responsive tumors. Phytoestrogens are present in many human foodstuffs including fruits (plum, pear, apple grape berries, ...), vegetables (beans, sprouts, cabbage, spinach, soybeans, grains, hops, garlic, onion,...), wine, tea, and they have been identified in a number of botanical dietary supplements. They include a wide variety of structurally different compounds such as isoflavones, mainly found in soy, lignans found in grains, stilbenes found in the skin of grapes. Other less investigated compounds include flavones, flavans, isoflavanes and coumestans. The estrogenic or antiestrogenic activity of any chemicals depends on the ability of the compound to interact with the ERs (ER α , ER β).

This article reported the knowledge about the activity of phytoestrogens from a pharmacological point of view for their estrogenicity or antiestrogenicity.

KEY WORDS: phytoestrogens, nutrition, bioactive compounds, soy, bone health.

Introduction

Within the past several years, the relation between diet and health has been accepted by the mainstream nutrition community, and in this connection interest in the physiological role of bioactive compounds present in plants has dramatically in-

creased over the last decade. As a complex mixture of chemicals, foods provide essential nutrients, requisite calories, and other physiologically active constituents that may be useful for life and health. A new paradigm for "optimal nutrition" may be evolving that would identify physiologically active components that contribute to diseases prevention. In thus functional foods concept is unifying the medical, nutritional and food sciences (Fig. 1). Collectively, plants contain several different families of natural bioactive products among which are compounds with weak estrogenic or antiestrogenic activity toward mammals. Of particular interest, in relation to human health, are these plant derived estrogens, or phytoestrogens, which embody several groups of non-steroidal estrogens widely distributed within the plant kingdom. Although *in vitro* and animal studies provide preliminary plausible mechanisms to explain how phytoestrogens act, the applications of diets rich in such compounds and their consequent biological effects still need to be fully examined, tested and confirmed through traditional scientific experimental pathway (Table I). Phytoestrogens are strikingly similar in chemical structure to the mammalian estrogen, estradiol, and bind to estrogen receptors (ERs) with the preference for ER β (1). This suggests that these compounds may exert tissue specific effects, beside other non receptor mediated biological activities, as antioxidant capacity and antiproliferative/antiangiogenic effects.

Natural estrogens are involved in a multiplicity of programmed events in target tissues as uterus, breast, pituitary gland and hormone responsive tumors. The initiation of estrogen action by all of the estrogens is considered to be the same in each target tissue. Estrogen firstly bind to the nuclear ER, then an estrogenic ligand causes a conformational change that encourages dimerization and interaction with either specific DNA sequences or a protein-protein interaction with AP-1 or Sp1 sites in the promoter region of estrogen-responsive genes (2). These events herald the biological effects of estrogen in the specific target tissue or tumor. A small percentage (2-3%) of ERs are located on the cell membrane and contribute to non genomic effects of estrogen (3). Two ERs are




Figure 1 - Phytoestrogens scientific research area.

Table I - Research needed to clarify possible roles of phytoestrogens in health.

- Identify the specific types of phytoestrogens that provide health benefits.
- Characterize the sources, dietary or supplemental.
- Define the effective dose of phytoestrogens that provide protection against a specific symptom.
- Determine the concentration at which pharmacologic doses become toxicologic problem.
- Identify new mechanisms by which the phytoestrogens produce protective effects.
- Identify specific binding proteins.
- Identify specific metabolites.
- Determine the effects of phytoestrogens on cells differentiations.
- Establish the pharmacokinetics of delivered doses.
- Identify the proportion of the population likely to respond positively to phytoestrogens.
- Examine more closely the dietary components relative to the diet as whole.

Modified from Bidlack WR and Wang W. In "Modern Nutrition in Health and Disease". Eds. Shils ME et al. 1999, 1823-1833.

currently known, ER α and ER β . Although the two ERs can be localized within the same cell, they vary in tissue distributions and can have different effects on mixed agonist and antagonist molecules.

Phytoestrogens include a wide variety of structurally diverse compounds such as isoflavones, mainly found in soy, lignans found in grains, stilbenes found in the skin of grapes. Other less investigated compounds include flavones, flavans, isoflavanes and coumestans (4). The estrogenic or antiestrogenic activity of any chemicals depends on the ability of the compound to interact with the ERs (ER α , ER β).

The aim of this article is to describe the substances that, up to date, has been validated from a pharmacological point of view for their estrogenicity or antiestrogenicity.

Phytoestrogens rich foods

Phytoestrogens are present in many human foodstuffs including fruits (plum, pear, apple grape berries...), vegetables (beans, sprouts, cabbage, spinaches, soybeans, grains, hops, garlic, onion, ...), wine, tea, and have been identified in a number of botanical dietary supplements (Table II). Plants vary intra- and inter-species in the types and concentrations of phytoestrogens due to variables in plant growth, soil, weather conditions and the age of plant. Chemically phytoestrogens are phenolic phytochemicals or polyphenols. These are the largest category of phytochemicals and the most widely distributed in the plant kingdom (5).

Polyphenols in plants show a multiple function, they act as antioxidants (protection against UV light), exert a protective action from insects, fungi, viruses and bacteria, and a visual attention-pollinator attraction (they are responsible of plant and flower colours) and they can also serve as feed-repellents and plant hormone controllers.

The study on phytoestrogens started in the '50s when it was realized that some plants derived substances could cause an estrogenic effect. Sheep that were grazing on pastures containing red clover had multiple fertility problems and it was shown that the clover present in this pastures had high amounts of isoflavones (6), in particular formononetin and biochanin A.

The phytoestrogens classification is controversial, anyway currently we can subdivide the phytoestrogens in four main classes: flavonoids (flavones and isoflavones), lignans, coumestans and stilbenes (Table III).

Flavonoids

They are the largest group of plant phenols including more than 4000 different compounds which are the most studied phytochemicals. The basic flavonoid structure allows a multitude of variations in chemical structure, giving rise to flavonols (quercetin, kaempferol, myricetin), flavones (apigenin, luteolin), flavanones (catechin, epicatechin), antocyanidins and isoflavonoids (glycitein, genistein, daidzein) (7). An important effect of flavonoids is the scavenging of oxygen-derived free radicals. The major source of isoflavonoids in the diet is from soy-based foods. The isoflavonoids from legumes, including genistein and daidzein, are the most studied phytoestrogens. They can exist as glycosides or as aglycones, the glucosides being readily hydrolyzed in the gut as their aglycones. The aglycones are easily transported across intestinal epithelial cells. Genistein has one-third the potency of estradiol when interacts with ER α , and one thousandth of the potency of estradiol when it interacts with ER β as determined by expression of luciferase reporter gene construct in kidney cells that have been cotransfected with ER α and ER β (8). Genistein may produce similar effects to estradiol in several different tissues as breast, ovarian, endometria, prostate, vascular, bone tissue and cell lines (9, 10). Furthermore, genistein induce also responses that are not associated with the ER, as the inhibition of tyrosine kinase and DNA topoisomerase (11). Such effect is produced even in the presence of the antiestrogen revealing a non genomic action that could explain a part of the difference between genistein and estradiol.

In vitro experimental systems also showed that flavonoids possess anti-inflammatory, antiallergic, antiviral and anticarcinogenic properties (12) and various of these molecules, notably isoflavonoids, are identified as phytoestrogens being able to bind estrogens receptors, and possess estrogenic or antiestrogenic activities (13, 14).

Lignans

They are constituents of higher plants, such as whole grains, legumes, vegetables and seeds with exceptionally high concentrations of lignans found in flaxseed. Although previously thought to be present only in higher plants, mammalian lignans have been detected in the biological fluids of humans and animals. The chemical structure of plant lignans is very different from that of mammalian lignans and most of the changes occur in the colon, liver and small intestine. Enterolactone and enterodiol are

Table II - Levels of isoflavones and lignans in various food sources. Values (in nanomoles per gram dry weight) were determined by isotope dilution gas chromatography mass spectrometry with selected ion monitoring. Mazur W, Adlercreutz H. 1998, modified.

Plant species (Common name)	Genistein	Daidzein	Secoisolariciresinol	Metairesinol
Soybean	993-3115	413-2205	< 1-8	< 1
Kidney bean	< 1-19	< 1-2	2-4	< 1
American groundnut	4-30	< 1	< 1-2	< 1
Chicpea	3-8	< 1-8	< 1	0
Pea	< 1	< 1	< 1	< 1
Lentil	< 1	< 1	< 1	< 1
Kudzu root	467	7283	< 1	< 1
Flaxseed	0	0	10-247	30
Sunflower seed	< 1	6	2	17
Peanut	2	1	8	< 1
Wheat bran	< 1	< 1	3	0
Barley	< 1	< 1	2	0
Rye bran	0	4	4	5
Strawberry	0	0	33	< 1
Cranberry	0	0	29	0
Bluberry	0	0	23	0
Raspberry	0	0	4	0
Red cabbage	< 1	< 1	4	< 1
Broccoli	< 1	< 1	11	< 1
Garlic	0	0	11	< 1
Zucchini	0	0	23	< 1
Carrot	0	0	10	< 1
Breetroot	0	0	3	< 1
Black tea	Trace	Trace	73	12
Green tea	Trace	Trace	75	5

metabolites of the plant lignans metairesinol e secoisolariciresinol, respectively (15). A clinical study showed that the excretion of the lignans, enterodiol and enterolactone, was significantly higher during a carotenoid (carrots and spinaches) and cruciferous (broccoli and cauliflowers) vegetable diet, than during a vegetable-free diet (16).

Coumestans

Legumes are the main source of coumestrol, the coumestan showing the highest estrogenic activity, and low level of coumestrol have been found also in brussel sprouts and spinaches, while the highest concentrations are reported in clover and in soybean sprouts.

Stilbenes

Recently, also the stilben resveratrol has been identified as a phytoestrogen. Resveratrol is a natural compound produced by some plants, such as grapevines, in response to injury. Peanuts are rich in resveratrol too. *Polygonium cuspidatum* roots, which have long been used in traditional oriental medicine, have been identified as the major active source of stilben phytoalexins. Trans resveratrol was firstly detected in grapevines in 1976 by Langcake and Pryce, who found that this compound was synthesized by leaf tissues in response to *Botrytis cinerea* fungal infection or exposure to ultraviolet light (17).

The biological activity of resveratrol was attested about fifteen years ago by the health benefits obtained by orally adminis-

Table III - Main chemical categories of phytoestrogens.

Lignans	Flavonols	Coumestans	Isoflavones	Stilbenes
Enterolactone	Quercetin	Cumestrol	Glycitein	Resveratrol
Enterodiol	Rutin		Genistein Daidzein	

tered resveratrol. An experimental study suggested that an average drinker of wine may, in the long term, absorb a quantity of resveratrol sufficient to explain the beneficial effect of red wine on human health (18). Resveratrol possesses anticancer properties, antioxidant activity and some observations have challenged the protective effects of resveratrol against atherosclerosis then preventing cardiovascular diseases. As a phytoestrogen it may favourably influence several physiological processes and given that resveratrol has a different structure, also its mechanism of action might differ somewhat from that of other flavonoids (17, 18).

Health beneficial effects of phytoestrogens

In the last two decades many clinical and epidemiological studies have been performed to test the health effects of foods and supplements rich in phytoestrogens. A recent review summarizes the main results from scientific studies (19). The effects of phytoestrogens administration are evaluated on different clinical endpoints as listed in Table IV.

Cardiovascular health

Estrogen may affect the vascular system both directly through the ERs located on vascular tissue, and indirectly through altering the lipoprotein profile (20). Initial epidemiologic studies showed that women taking hormone replacement therapy (HRT) were 50% less likely to experience severe cardiovascular disease (CVD) than women not assuming HRT (21). Lately, a more comprehensive study performed by the Women's Health Initiative has demonstrated a significant increase in CVD in the first year of HRT use, remaining is still elevated after 5 years of continued use (22-24). There are several clinical studies that have examined the effect of phytoestrogens on CVD. Isoflavonoids or soy/soy proteins and flaxseed have the ability to lower total cholesterol (25, 26), LDL cholesterol (25, 27) and to raise HDL cholesterol (28, 29). On the contrary, other studies showed no effect of isoflavonoids derived from soy or red clover on serum cholesterol levels or plasma lipids (30, 31). Although no clinical studies showed that resveratrol improves cardiovascular function, the consumption of red wine has been linked to the French Paradox, phenomenon observed in French people who have a diet similar to the North American diet with a significantly lower rate at CVD (32).

Table IV - Summary of phytoestrogen clinical studies.

Clinical endpoints	Positive results	Total
Maintaining bone density	11	15
Relief menopause symptoms	4	17
Cardiovascular benefit	25	38
Cancer prevention	7	13
Hormon levels/menstrual cycle	12	19
Effect of hormones in men	0	1
Immune system	1	1
Neurological	5	5
Totals	64	105

Totals are less than the sum of the studies since some studies examined several clinical endpoints.

Modified from Cornwell et al. 2004 (ref. 19).

Cancer

There is a large body evidence coming from epidemiologic studies showing people who consume high amounts of isoflavonoids in their diets have lower rates of occurrence of several cancers including breast, prostate and colon cancer (33).

The protective effect of phytoestrogens on cancer may be due to their role in lowering circulating levels of unconjugated sex hormones. Estrogens mainly circulate as inactive conjugates of sex hormones binding globulin (SHBG) or albumin (34). Dietary supplementation with soy isoflavonoids or lignans produced an increase of the levels of SHBG in postmenopausal women, lowering the serum levels of estradiol (35, 36). Furthermore, higher intakes of soy products and flaxseeds produced a significant decrease of the urinary excretion of genotoxic estrogen metabolites (37). Moreover, the role of phytoestrogens in preventing cancer in women may be related to changes in menstrual cycle length (38). Increases in menstrual cycle length together with eating a diet rich in phytoestrogens correlate with a decreased rate of hormone-dependent cancers development, including endometrial, ovarian, and breast cancer (39).

Menopausal symptoms

Epidemiological studies show that Asiatic women experience hot flashes less frequently than the Western women (20% versus 80%, respectively).

Diet has been included among the different reasons proposed to explain such proven difference. Indeed, Asian diet is known to be rich in phytoestrogens and even though only few clinical trials have been conducted to evaluate the role of these bioactive substances in regulating the menopause symptoms, most data from randomized studies indicate a significant drop in the severity and frequency of menopausal symptoms. However, women given placebos also demonstrated a decline in menopausal symptoms (40, 41). The variability in frequency and severity of the hot flashes and the high placebo-response rate make these clinical trials difficult to interpret and, currently, they are not sufficient to demonstrate the effectiveness of phytoestrogens in reducing menopausal symptoms. However, considering the lower than expected effectiveness of HRT (22), it is not surprising that many new studies, planned to show the benefit in the reduction of menopause symptoms with phytoestrogen supplementation, are in progress.

Soy and cognitive function

There is a clear evidence that treatment of postmenopausal women with mammalian estrogens improves memory and may alleviate the decline of cognitive function and the risk of dementia (42). A few studies have examined the effect of phytoestrogens on cognitive function. Data from a follow-up study of the cognitive functions showed improvement in pictures recall, sustained attention and ability to plan tasks, but on the other side these women did not demonstrate any improvement in mood or sleepiness, suggesting a specific action on frontal lobe functions (43). In summary, there are too few studies to evaluate whether phytoestrogens may exert some effects on cognitive abilities resulting in a better quality of life in postmenopausal women.

A nutritional model: soy-foods and bone health

Soy intake is part of the regular diet of the Asian populations. Observations that soy consuming populations have lower hip

fracture rate have given rise to the hypothesis that the intake of soy-proteins and/or soy-derived isoflavonoid phytoestrogens may be protective for bone health (44). Researchers have long recognized that Asian women, consuming traditional diet, enjoy better cardiovascular and bone health than their counterparts in Western societies. Nutrition epidemiologists believe that this may partly be the result of the soy rich diet. The scientific interest of isoflavones began with epidemiological studies of elderly women in Asian countries who consume high levels of isoflavones from soy products. The studies showed a positive correlation between a lower prevalence of hip fractures and the intake of soy-food (45). However, this type of association is inconclusive, as Asian women have different hip geometry than Caucasian women (46). Further epidemiological studies, conducted in Japan and in Hong Kong to directly examine the linkage between dietary soy-foods intake and lumbar spine bone mineral density (BMD) in Asian women, showed a significantly greater BMD in women consuming the highest level of dietary isoflavones compared to those who consumed the least (47). These results do not demonstrate how this protective effects of soy and/or their isoflavones is related to the length of exposure that, usually, for the majority of Asians is over the entire life span (48).

Various studies on animal model, using ovariectomized female rats fed with soy-foods or soy derivatives have shown comparable bone-sparing effects of 17β -estradiol and soy protein isolate (49), genistein (50) or daidzein (51).

Clinical trials on the effects of soy isoflavones on bone are too limited and have shown mixed results (52, 53). Studies have used both soy protein isolate with isoflavones and isolated isoflavones, but the published clinical studies have been of short duration with only one 12-months trial. The 6 months studies demonstrated promising effects of soy protein isolates containing isoflavones on spine BMD in peri- and postmenopausal women, but they were too short to adequately evaluate the impact of an intervention on BMD (52). However, the 12 months trial provided confirmations of the positive effect of genistein on bone (53), although no consistent changes in biochemical markers of bone turnover have been reported.

None of the studies in both animals and humans have assessed the effects of soy isoflavones on calcium metabolism. Such information is essential in ascertaining the mode of action of isoflavones on the skeleton. In addition to the estrogenic role of isoflavones in bone health, it has been also demonstrated that many soy foods are a good source of calcium and soy proteins are less calciuric than animal proteins. Although soybeans contain both oxalates and phytates, which are inhibitors of calcium absorption, calcium bioavailability from soy beans has been shown to be equivalent to that from milk (54). An exception is represented by calcium-fortified soy beverage from which calcium absorption was reported to be 75% of that from cows milk (55). In comparison to animal proteins, soy proteins contain less sulfur-containing aminoacids. One study found that subjects consuming animal protein-based diets excreted 150 mg of urinary calcium per day in comparison with about 100 mg of those subjects consuming a soy protein-based diet (56).

In conclusion, the habitual intake of soy, as traditional Asian food, appears to be beneficial to bone health, though the effective or optimal dosage is still unclear. The soy-bone action could be mediated through its estrogenic or calcium conserving effects. In addition, soy intake also contributes to an increase in high quality protein intake. Therefore, this traditional dietary practice should be encouraged and preserved in Asian populations.

Although European countries have no soy consumption tradition, another plant estrogen group, known as lignans, seems to have a positive impact on bone health in European countries,

as well as in the vegetarian population. This is due to the relatively high levels of these compounds in certain grains, especially in rye, as well as in flaxseed that are part of the daily diet in these populations. Interestingly, there is a striking similarity between the European vegetarian and Asian-Japanese populations, exhibiting a lower incidence of osteoporosis compared to the non-vegetarian populations (57).

A pharmacological model: phytoestrogens and bone health

Most of the studies suggest that phytoestrogens are somewhat effective in maintaining BMD in postmenopausal women (58-65). Moreover, recent results from the Women's Health Initiative Study, showing an unexpected lack of cardioprotective effects of HRT (22), pushed the research for alternative and natural strategies for managing and preventing osteoporosis. The last full review (66) about the dietary phytoestrogens and their effect on bone justifies the bone-conserving properties of isoflavones by the following bodies of experimental evidences showing tight similarities with an experimental pharmacological model from *in vitro* studies of cultured bone cells through animal models of osteoporosis to epidemiological and intervention studies on humans.

Most of the *in vitro* studies with human and animal osteoblasts and osteoblast-like cell-lines have shown that daidzein and genistein have a stimulatory effect on protein synthesis and on alkaline phosphatase release (67, 68). This effect is blocked by the addition of actinomycin or cycloheximide, suggesting that these isoflavones influence transcriptional or translational events (66). More recently, genistein has been found to stimulate the production of osteoprotegerin (OPG) by human osteoblasts, providing a further mechanism for the bone-sparing effects of soy isoflavones. Besides ER-dependent processes, genistein and daidzein both suppress osteoclast activity by several mechanisms, including apoptosis, activation of protein tyrosine phosphatase, inhibition of cytokines, changes in intracellular Ca^{++} , membrane depolarization and antioxidant activity, much like many other polyphenols (69, 72). In some cases the antioxidant effect occurs in the nM range. Furthermore a positive synergy between phytoestrogens and other antioxidants has been also described (73).

A number of observational and dietary intervention studies confirm the general findings from *in vitro* effects of phytoestrogens on human bone cells in culture. Thus far, observational or epidemiologic studies (74, 75) and dietary intervention studies (76, 81) have shown significant relationships between phytoestrogens and surrogate markers of bone turnover such as urinary calcium, magnesium and phosphorous, hydroxyproline, and collagen cross-links and serum markers including bone specific alkaline phosphatase, osteocalcin, insulin-like growth factor I (IGF-I), and interleukin 6 (Tables Va and Vb). Most of the observational studies have been performed in women living in Countries where the indigenous population have relatively high phytoestrogen intake, mostly related to the soy protein foods.

Conclusions

Since it has now been established that lifestyle and particularly nutritional habits significantly contribute to the occurrence of different rates of degenerative disorders, such as cardiovascular diseases, osteoporosis, cognitive disability, and cancer, in recent years Eastern and Western governments and industries have started to invest in the evaluation of the health effects of phytochemicals contained in the diet. This aspect is becoming a main feature of preventive medicine since life expectation is growing in the Western World population.

Table Va - Intervention studies with phytoestrogens and bone health in women including findings on BMD and BMC.

Reference	Subjects	Intervention (protein type and daily isoflavone level)	Study length (months)	Findings BMD or BMC endpoint by DXA
Dalais et al., 1998	Postmenopausal n = 45	Soy grits 45 g Wheat kibble 45 g Flaxseed 45 g	3	All 3 groups had increased in BMC. Soy group 5.2%, Flax group 5.2% and Control group 4.0%
Potter et al., 1998	Postmenopausal n = 66	Casein 40 g/d Soy 40 g/56 mg Soy 40 g/90 mg Ca supplemented	6	+ 2.2% increase in lumbar spine BMD in soy 90 mg isoflavone group. The 56 mg isoflavone group unchanged No changes in other sites.
Clifton-Bligh et al., 2001	Postmenopausal n = 46	Clover-derived tablets 28.5, 57 and 85.5 mg	6	BMD at proximal radio and ulna increased 4.1% with 57 mg/d and 3.0% with 85.5 mg/d. The 18.5 mg/d remained unchanged. No increase in endometrial thickness was seen in any group.
Anderson et al., 2002	Young healthy Adult women n = 27, age 21-25 y	Isoflavone-rich diet, 90 mg, compared with control diet	12	No effect of soy diet on BMD or BMC in healthy, menstruating women

Modified from Setchell KDR et al., 2003 (68).

BMC, bone mineral content; BMD, bone mineral density; DXA, dual-energy X-ray absorptiometry; uDpy, urinary deoxyypyridinoline; PTH, parathyroid hormone; BAP, bone-specific alkaline phosphatase; IGF-I, insulin-like growth factor; ERT, estrogen replacement therapy; NT_x, crosslinked N-telopeptides of type I collagen; OC osteocalcin; Ca, calcium; ALP, alkaline phosphatase.

Table Vb - Intervention studies with phytoestrogens and bone health in women including findings on bone markers.

Reference	Subjects	Intervention (protein type and daily isoflavone level)	Study length	Findings Bone markers endpoints
Wong, 2000	Postmenopausal n = 6 Open pilot study Mean age 55.4 y	Soy isoflavones 160 mg/d	6 wk	Resorption markers: uDpy -7 ± 41%, Urinary Ca concentration -12 ± 46% s PTH +33 ± 60% Urinary Ca excretion -5 ± 29% Bone formation markers: sOC 9 ± 15% Serum BAP -16 ± 23%, IGF-I -8 ± 27% Changes are of similar magnitude to those reported for ERT.
Scheiber, 2001	Postmenopausal n = 42 Mean age 55.5 y Open pilot study	Whole soy foods, 60 mg isoflavones/d No Ca supplementation	3 mo	Resorption markers: serum ALP unchanged, urinary NT _x decreased 13.9% Formation markers: serum OC increased 10.3%.
Lu et al., 2002	Postmenopausal n = 12 Age range: 49-66 y	Soy milk 1.08 L/d ≈ 112 mg isoflavones	4 mo	Increase in uDpy 21% and serum BAP 18%, increase in OC 34%. Values returned to prediet level 4 mo after diet. No estrogenic effects on uterus. No changes in serum levels of PTH, follicle-stimulating hormone or estradiol.

Modified from Setchell KDR et al., 2003 (68).

BMC, bone mineral content; BMD, bone mineral density; DXA, dual-energy X-ray absorptiometry; uDpy, urinary deoxyypyridinoline; PTH, parathyroid hormone; BAP, bone-specific alkaline phosphatase; IGF-I, insulin-like growth factor; ERT, estrogen replacement therapy; NT_x, crosslinked N-telopeptides of type I collagen; OC osteocalcin; Ca, calcium; ALP, alkaline phosphatase.

Up to date, it is not still completely clear if the foods rich in such compounds may really be protective on human health and, in the event of, at which daily regimen they should be assumed to exert a real pharmacological action. Moreover, non estrogenic compounds are coexisting with phytoestrogens in the same plant-derived food and the role that they may play on both activity and bioavailability of phytoestrogen themselves has not been elucidated. Since at present industries can pro-

duce extract compounds from this foodstuffs, researchers may take advantage to plan experimental studies and clinical trials in which these molecules can be tested in relation to biomarkers and other functional parameters connected with human pathophysiology. Consequently, the possibility of testing the purified phytochemical compounds, both in in vitro and in vivo experimental models, may offer the opportunity to corroborate data obtained from epidemiological studies.

Unfortunately, due to the great diversity of phytoestrogen compounds, including different bioavailability, pharmacokinetics, pharmacological properties and metabolic fates, it is quite complex to define, assess and understand their precise effects on human health since large and time extended intervention studies are needed.

Osteoporosis represents one of the human disease models more largely studied for the potential therapeutic effects of phytoestrogens.

Currently, the results from the few studies on bone health are seductive but too few to draw definitive conclusions. Supporting data from *in vitro* and *in vivo* studies of models of osteoporosis strongly shows bone-sparing effects from dietary phytoestrogens. Such data may justify large-scale clinical dietary intervention studies of phytoestrogens in early future.

Finally, the preliminary data in this field suggest to include phytoestrogen rich foods in the health foods sector and push scientists to isolate the active molecules to be used as new potential drugs.

References

1. Cassidy A. Potential risks and benefits of phytoestrogen-rich diets. *Int J Vitam Nutr Res.* 2003;Mar;73(2):120-6.
2. Jordan VC, Mc Gregor Schafer J, Levenson AS, et al. Molecular classification of estrogens. *Cancer Res.* 2001;September 15(61):6619-23.
3. Chen DB, Bird IM, Zheng J, et al. Membrane estrogen receptor-dependent extracellular signal-regulated kinase pathway mediates acute activation of endothelial nitric oxide synthase by estrogen in uterine artery endothelial cells. *Endocrinology.* 2004;145:113-25.
4. Mueller SO. Overview of *in vitro* tools to assess the estrogenic and antiestrogenic activity of phytoestrogens. *J Chromatog B.* 2002;777:155-65.
5. UCLA Center for Human Nutrition Phytoestrogens at http://www.cellinteractive.com/ucla/natural_remedies/phytoestrogens.html 26/04/2004.
6. Rossiter RC, Beck AB. Physiological and ecological studies on the estrogenic isoflavones in subterranean clover (*Tifolium subterraneum*) I. Effects of temperature. *Aust J Agrc.Res.* 1996;17:29-37.
7. UCLA Center for Human Nutrition – Flavonoids and health at http://www.cellinteractive.com/ucla/natural_remedies/flavonoids.html 26/04/2004.
8. Kuiper GG, Lemmen JG, Carlsson B et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β . *Endocrinology.* 1998;139:4252-4263.
9. Wang D, Gutkowska J, Marcinkiewicz M et al. Genistein supplementation stimulates the oxytocin system in the aorta of ovariectomized rats. *Cardiovasc Res.* 2003;57:186-194.
10. Zhou S, Turgeman G, Harris Stephen E et al. Estrogens activate bone morphogenetic protein-2 gene transcription in mouse mesenchymal stem cells. *Mol Endocrinol.* 2003;17:56-66.
11. Jonas J, Plant T, Gilon P et al. Multiple effects and stimulation of insulin secretion by the tyrosine kinase inhibitor genistein in normal mouse islets. *Br J Pharmacol.* 1995;114:872-880.
12. Nijveldt RJ., van Nood E., van Hoorn DEC et al. Flavonoids: a review of probable mechanisms of action and potential applications. *Am J Clin Nutr.* 2001;74:418-25.
13. Van der Woude H, Gliszczynska-Swiglo A, Struijs K. et al. Biphasic modulation of cell proliferation by quercetin at concentrations physiologically relevant in humans. *Cancer Lett.* 2003;Oct 8, 200(1):41-7.
14. Prouillet C, Mazière JC, Mazière C et al. Stimulatory effect of naturally occurring flavonols quercetin and kaempferol on alkaline phosphatase activity in MG-63 human osteoblast through ERK and estrogen receptor pathway. *Biochem Pharmacol.* 2004; 67:1307-13.
15. Tham DM, Gardner CD, Haskell WL. Potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological and mechanistic evidence. *J Clin Endocrinol Metab.* 1998;83:2223-35.
16. Kirkman LM, Lampe JW, Campbell DR et al. Urinary lignan and isoflavonoid excretion in man and women consuming vegetable and soy diet. *Nutr Cancer.* 1995;24:1-12.
17. Frémont L. Biological effects of resveratrol. *Life Sciences.* 2000; 66(8):663-73.
18. Bertelli A, Bertelli AA, Gozzini A et al. Plasma and tissue resveratrol concentrations and pharmacological activity. *Drugs Exp Clin Res.* 1998;24(3):133-8.
19. Cornwell T, Cohick W, Raskin I. Dietary phytoestrogens and health. *Phytochemistry.* 2004;65:995-1016.
20. Rubanyi GM, Johns A, Kaiser K. Effect of estrogen on endothelial function and angiogenesis. *Vasc Pharmacol.* 2002;38:89-98.
21. Lissin LW, Cook JP. Phytoestrogens and cardiovascular health. *J Am Coll Card.* 2000;35:1403-1410.
22. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. *JAMA.* 2002;288:321-33.
23. Hays J, Ockene JK, Brunner RL et al. Women's Health Initiative Investigators. Effects of estrogen plus progestin on health related quality of life. *New Engl J Med.* 2003;348:1835-7.
24. Manson JE, Hsia J, Johnson KC et al. The Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. *New Engl J Med.* 2003;349:523-34.
25. Lemay A, Dodin S, Kadri N et al. Flaxseed dietary supplement versus hormone replacement therapy in hypercholesterolemic menopausal women. *Obstet Gynecol.* 2002;100:495-504.
26. Teede HJ, Dalais FS, Kotsopoulos D et al. Dietary soy has both beneficial and potentially adverse cardiovascular effects: a placebo controlled study in men and postmenopausal women. *J Clin Endocrinol Metab.* 2001;86:3053-60.
27. Jayagopal V, Albertazzi P, Kilpatrick ES et al. Beneficial effects of soy phytoestrogen intake in postmenopausal women with type 2 diabetes. *Diabetes Care.* 2002;25:990-4.
28. Potter S, Baum J, Teng H et al. Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. *Am J Clin Nutr.* 1998;68:1375-9.
29. Sanders TAB, Dean TS, Grainger D et al. Moderate intakes of intact soy protein rich in isoflavones compared with ethanol-extracted soy protein increase HDL but do not influence transforming growth factor beta(1) concentrations and hemostatic risk factors for coronary heart disease in healthy subjects. *Am J Nutr.* 2002;76: 373-377.
30. Howes JB, Sullivan D, Lai N et al. The effect of dietary supplementation with isoflavones from red clover on the lipoprotein profiles of postmenopausal women with mild to moderate hypercholesterolemia. *Atherosclerosis.* 2000;152:143-7.
31. Dewell A, Hollenbeck CB, Bruce B. The effects of the soy derived phytoestrogens on serum lipids and lipoproteins in moderately hypercholesterolemic postmenopausal women. *J Clin Endocrinol Metab.* 2002;87:118-21.
32. Asby J, Tinwell H, Pennie W et al. Partial and weak estrogenicity of the red wine constituent resveratrol 4: consideration of its superagonist activity in MCF-7 cells and its suggested cardiovascular protective effects. *J Appl Toxicol.* 1999;19:39-45.
33. American Institute for Cancer Research. Food Nutrition and the Prevention of Cancer. A Global Perspective. World Cancer Research Fund. Washington. 1997.
34. Dotsch J, Dorr HG, Wildt L. Exposure in endogenous estrogens during lifetime. *Endocrine disruptors Part 1.* Ed. Metzler M. Berlin Heidelberg: Springer-Verlag. 2001:83-99.
35. Hutchins AM, Martini MC, Olson BA et al. Flaxseed consumption influences endogenous hormone concentrations in postmenopausal women. *Nutr Cancer.* 2001;39:58-65.
36. Berrino F, Bellati C, Secreto et al. Reducing bioavailable sex hormones through a comprehensive change in diet: the diet and androgens (DIANA) randomized trial. *Cancer Epidemiol Biomarkers Prev.* 2001;10:25-33.
37. Xu X, Duncan AM, Merz BE et al. Soy consumption alters endogenous estrogen metabolism in postmenopausal women. *Cancer Epidemiol Biomarkers Prev.* 2000;7:1101-1108.
38. Nagata C, Takatsuka N, Inaba S et al. Effect of soymilk consumption

- tion on serum estrogen concentrations in premenopausal Japanese women. *J Natl Cancer Inst.* 1998;90:1830-1835.
39. Tsourounis C. Clinical effects of phytoestrogens. *Clin Obst Gynecol.* 2004;44:836-842.
 40. Tice JA, Ettinger B, Ensrud K. Phytoestrogen supplements for the treatment of hot flashes: the isoflavone clover extract (ICE) study: a randomized controlled trial. *JAMA.* 2003;290:207-214.
 41. Nikander E, Kikkinen A, Metsa-Heikkilä M et al. A randomized placebo-controlled crossover trial with phytoestrogens in treatment of menopause in breast cancer patients. *Obst Gynecol.* 2003; 101:1213-1220.
 42. Yaffe K, Sawaya G, Lieberburg I et al. Estrogen therapy in postmenopausal women: Effects on cognitive function and dementia. *JAMA.* 1998;279:688-95.
 43. Duffy R, Wiseman H, File SE. Improved cognitive function in postmenopausal women after 12 weeks of consumption of a soya extract containing isoflavones. *Pharmacol Biochem Behav.* 2003;75: 721-29.
 44. Messina MJ. Legumes and soybeans: overview of their nutritional profiles and health effects. *Am J Clin Nutr.* 1999;70:439S-50S.
 45. Lacey JM and Anderson JJB. Older women in Japan and the United States: physical and nutritional comparisons. In Takahashi ed. *Bone Morphometry: Proceedings of the Fifth International Congress.* Nishimura, Japan. 1991:562-5.
 46. Nakamura T, Turner CH, Yoshikawa T et al. Do variations in hip geometry explain differences in hip fracture risk between Japanese and white Americans? *J Bone Miner Res.* 1994;9(7):1071-6.
 47. Mei J, Yeung SS, Kung AW. High dietary phytoestrogen intake is associated with higher bone mineral density in postmenopausal but not premenopausal women. *J Clinical Endocrinol Metabol.* 2001;11:5217-21.
 48. Cai DJ, Spence LA, Weaver CM. Soy isoflavones and bone health. In New SA and Bonjour JP, eds *Nutritional aspects of bone health.* Cambridge: The Royal Society of Chemistry. 2003:421-438.
 49. Ajrmandi BH, Alekel L, Hollis BW et al. Dietary soybean protein prevents bone loss in an ovariectomized rat model of osteoporosis. *J Nutr.* 1996;126:161-167.
 50. Fanti P, Monier-Faugere MC, Geng Z et al. The phytoestrogen genistein reduces bone loss in short term ovariectomized rats. *Osteoporosis Int.* 1998;8:274-281.
 51. Ishida H, Uesugi T, Hirai K et al. Preventive effects of the plants isoflavones, daidzein and genistein on bone loss in ovariectomized rats fed a calcium-deficient diet. *Biol Pharm Bull.* 1998; 21:62-66.
 52. Alekel L, St. German A, Peterson CT et al. Isoflavone-rich soy protein isolate exerts significant bone-sparing in the lumbar spine of perimenopausal women. *Am J Clin Nutr.* 2000;72:844-852.
 53. Morabito N, Crisafulli A, Vergara C et al. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study. *J Bone Miner Res.* 2002;17:1904-1912.
 54. Poneros AG, Erdman JW Jr. Bioavailability of calcium from tofu, tortillas, nonfat dry milk and mozzarella cheese in rats, effect of supplemental ascorbic acid. *J Food Sci.* 1993;58:382-384.
 55. Heaney RP, Dowell MS, Rafferty K et al. Bioavailability of the calcium in fortified soy imitation milk some observations on method. *Am J Clin Nutr.* 2000;71:1166-1169.
 56. Breslau NA, Brinkley L, Hill KD et al. Relationship of animal protein rich diet to kidney stone formation and calcium metabolism. *J Clin Endocrinol Metab.* 1988;66:140-146.
 57. Brouns F. Soy isoflavones: a new and promising ingredient for the health foods sector. *Food Res Int.* 2002;35:187-93.
 58. Dalais FS, Rice GE, Wahlqvist ML et al. Effects of dietary phytoestrogens in postmenopausal women. *Climacteric.* 1998;1:124-9.
 59. Kaardinal AFM, Morton MS, Bruggemann-Rotgans IEM et al. Phytoestrogen excretion and rate of bone loss in postmenopausal women. *Eur J Clin Nutr.* 1998;52:850-5.
 60. Alekel DL, Germain AS, Peterson CT et al. Isoflavone rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. *Am J Clin Nutr.* 2000;72:844-52.
 61. Ho SC, Chan SG, Yi Q et al. Soy intake and the maintenance of peak bone mass in Hong Kong Chinese women. *J Bone Miner Res.* 2001;16:1363-9.
 62. Mei J, Yeung SS, Kung AW. High dietary phytoestrogen intake is associated with higher bone mineral density in postmenopausal but not premenopausal women. *J Clin Endocrinol Metab.* 2001;86: 5217-21.
 63. Chiechi LM, Secreto G, D'Amore M et al. Efficacy of soy rich diet in preventing postmenopausal osteoporosis: the Menfis randomized trial. *Maturitas.* 2002;42:295-300.
 64. Kim MK, Chung BC, Yu VY et al. Relationships of urinary phytoestrogen excretion to BMD in postmenopausal women. *Clin Endocrinol.* 2002;56:321-8.
 65. Morabito N, Crisafulli A, Vergara C et al. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study. *J Bone Miner Res.* 2002;17:1904-12.
 66. Setchell KDR, Lydeking-Olsen E. Dietary phytoestrogens and their effect on bone: evidence from in vitro and in vivo, human observational, and dietary intervention studies. *Am J Clin Nutr.* 2003;78:593S-609S.
 67. Sugimoto E, Yamaguchi M. Anabolic effect of genistein in osteoblastic MC3T3-E1 cells. *Int J Mol Med.* 2000;5(5):515-20.
 68. Yamaguchi M, Sugimoto E. Stimulatory effect of genistein and daidzein on protein synthesis in osteoblastic MC3T3-E1 cells: activation of aminoacyl-tRNA synthetase. *Mol Cell Biochem.* 2000; 214(1-2):97-102.
 69. Blair HC, Jordan SE, Peterson TG et al. Variable effects of tyrosine kinase inhibitors on avian osteoclastic activity and reduction of bone loss in ovariectomized rats. *J Cell Biochem.* 1996;61:629-37.
 70. Williams JP, Jordan SE, Barnes S et al. Tyrosine kinase inhibitor effects on avian osteoclastic acid transport. *Am J Clin Nutr.* 1998; 68(suppl):1369S-74S.
 71. Okamoto F, Okabe K, Kajiji H. Genistein, a soybean isoflavone, inhibits inward rectifier K⁺ channels in rat osteoclasts. *Jpn J Physiol.* 2001;51:501-9.
 72. Gao YH, Yamaguchi M. Suppressive effects of genistein on rat bone osteoclasts: apoptosis is reduced through Ca⁺⁺ signaling. *Biol Pharm Bull.* 1999;22:805-9.
 73. Gao YH, Yamaguchi M. Suppressive effect of genistein on rat bone osteoclasts: involvement of protein kinase inhibition and protein tyrosine phosphatase activation. *Int J Mol Med.* 2000;5:261-7.
 74. Chin-Dusting JP, Fisher LJ, Lewis TV et al. The vascular activity of some isoflavone metabolites: implications for cardioprotective role. *Brit J Pharmacol.* 2001;133:595-605.
 75. Patel RP, Boersma B, Crawford JH et al. Antioxidant mechanisms of isoflavones in lipid systems: paradoxical effects of peroxyl radical scavenging. *Free Rad Biol Med.* 2001;31:1570-81.
 76. Horiuchi T, Onouchi T, Takahashi M et al. Effect of soy protein on bone metabolism in postmenopausal women. *Osteoporosis.* 2000; 11:721-4.
 77. Somekawa Y, Chiguchi M, Ishibashi T et al. Soy intake related to menopausal symptoms, serum lipids, and bone mineral density in postmenopausal Japanese women. *Obstet Gynecol.* 2001;97:109-15.
 78. Pansini F, Bonaccorsi G, Albertazzi P et al. Soy phytoestrogens and bone. In: *Proceedings of the North American Menopause Society.* 1997:44 (abstr).
 79. Wangen KE, Duncan AM, Merz-Demlow BE et al. Effects of soy isoflavones on markers of bone turnover in premenopausal and postmenopausal women. *J Clin Endocrinol Metab.* 2000;85:3043-9.
 80. Wong WW. Effects of soy isoflavones on blood lipids, blood pressure and biochemical markers of bone metabolism in postmenopausal women. *J Nutr.* 2000;130:686S (abstr).
 81. Ajrmandi BH, Khalil DA, Lucas EA et al. Soy protein with its isoflavones improves bone markers in middle aged and elderly women. *FASEB J.* 2001;15:A728 (abstr).
 82. Scheiber M, Liu J, Subbiah MT et al. Dietary soy supplementation reduces LDL oxidation and bone turnover in healthy postmenopausal women. *Menopause.* 2001;8:384-92.
 83. Cook A, Pennington G. Phytoestrogen and multiple vitamin/mineral effects on bone mineral density in early postmenopausal women: a pilot study. *J Women Health.* 2002;11:53-60.